Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Only a year and a half apart, both chairmen of ST Dongshi have been dismissed by the Board of Directors | Quick read of the announcement.
① The chairman of ST Dongshi has been removed by the Board of Directors, with several directors believing that the chairman's tenure saw a continued deterioration in the company's operational conditions, chaotic internal management, and unclear strategic direction, which severely affected the company's operation and future development; ② This is the second chairman to be dismissed at ST Dongshi within a year and a half, and both are brothers; ③ Currently, the company also faces operational pressure and issues with the controlling shareholder's illegal appropriation of company funds.
Earnings Call Summary | Kaiser Aluminum(KALU.US) Q4 2024 Earnings Conference
Kaiser Aluminum Q4 Adj EPS $0.33 Misses $0.64 Estimate, Sales $765.00M Beat $735.15M Estimate
Targeting the original controlling shareholder Zhong Zhu Group, Zhong Zhu Healthcare Holding initiates multiple lawsuits | Quick read announcement
① This evening, Zhong Zhu Healthcare Holding announced three litigation cases, with a total amount involved of 0.219 billion yuan. ② Since January 22 of this year, there have been six lawsuits in which Zhong Zhu Healthcare Holding has been the plaintiff, related to the company's previous Equity Transfer agreement. ③ The company's former controlling shareholder, Zhong Zhu Group, can be seen in the defendant's seat.
The first company in the Year of the Snake! *ST Dayao has had a Market Cap below 0.5 billion for 20 consecutive days, triggering a mandatory (Delisted) | Quick Read Announcement.
① Due to the total market value of Stocks closing below 0.5 billion yuan for 20 consecutive Trading days, *ST Pharmaceutical will become the first company to be (Delisted) in the Year of the Snake. ② The company expects that the total profit, Net income, and Net income after non-recurring items for 2024 will all be negative, and the revenue after deducting income unrelated to the core Business and income without commercial substance will be below 0.3 billion yuan.